Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q
On May 21, 2024, Cosmos Health received an additional delinquency letter from Nasdaq for failing to file its Form 10-Q for Q1 2024 and its Annual Report on Form 10-K for 2023.
The initial failure notice was issued on April 17, 2024, giving the company until June 17, 2024, to submit a plan to regain compliance. If Nasdaq accepts the plan, Cosmos Health could get an extension until October 14, 2024, to meet the compliance requirements. Failure to comply could result in delisting, but the company's shares remain listed for now.
CEO Greg Siokas expressed confidence in regaining compliance. The situation could impact investor confidence and stock performance (NASDAQ: COSM).
- The company remains listed on Nasdaq despite delinquency.
- Company has until June 17, 2024, to submit a compliance plan.
- Potential extension until October 14, 2024, if the plan is accepted.
- CEO Greg Siokas is confident in regaining compliance.
- Received an additional delinquency letter from Nasdaq.
- Failure to file Form 10-Q for Q1 2024.
- Annual Report on Form 10-K for 2023 remains delinquent.
- Possibility of delisting if compliance is not regained.
- Potential negative impact on investor confidence and stock performance.
Cosmos Health's receipt of a delinquency letter from Nasdaq points toward operational inefficiencies. The critical failure to file necessary financial documents such as the Form 10-K and 10-Q indicates internal management and possibly cash flow issues. For investors, this raises concerns about the company’s financial health and governance. Delinquency letters can cast a shadow over investor confidence, leading to potential stock price volatility in the short term.
Another important aspect to consider is the possible extension for compliance. A failure to secure an extension or submit a definitive plan could lead to delisting from Nasdaq, which is a major red flag for investors. Delisting can severely limit the stock's liquidity and accessibility, affecting both institutional and retail investors negatively.
Moreover, this highlights the importance of timely and transparent financial reporting, which is a cornerstone of investor trust and regulatory compliance. Historically, companies with repeated compliance issues often see a decrease in investor confidence and market performance.
From a legal perspective, the delinquency letter from Nasdaq is a significant disclosure. Nasdaq Listing Rule 5250(c)(1) requires timely filing of periodic financial reports. The failure to comply threatens the company's Nasdaq listing status. If Cosmos Health fails to submit a viable compliance plan or receive an extension, it could face delisting, which has severe repercussions on the company's legal standing and its ability to raise capital.
For investors, it's critical to monitor how Cosmos Health responds to this letter. The company's management must demonstrate robust governance and transparency to regain compliance. Historically, companies that fail to maintain listing standards often face legal scrutiny and a drop in shareholder value.
Understanding the legal weight of such delinquency letters is essential. They serve as formal notices that, if unheeded, can escalate to hearings and potential delisting—each step increasing legal complexities and risks for the company and its investors.
CHICAGO, IL / ACCESSWIRE / May 24, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that on May 21, 2024, it received an additional delinquency letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it continues to be out of compliance with Nasdaq's continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1) due to the Company's failure to timely file its Form 10-Q for the period ended March 31, 2024, as well as remaining delinquent in filing its Annual Report on Form 10-K for the period ended December 31, 2023 (the "Initial Delinquent Filing").
In the initial delinquency letter dated April 17, 2024, Nasdaq provided the Company with 60 days, or until June 17, 2024, to submit a definitive plan (the "Plan") addressing how it intends to regain compliance with Nasdaq's Listing Rules. If accepted, Nasdaq can grant an extension of up to 180 calendar days from the due date of the Initial Delinquent Filing, or until October 14, 2024, to regain compliance. If Nasdaq does not accept the Company's Plan, the Company will have the opportunity to appeal that decision to a Hearings Panel.
The additional delinquency letter has no immediate effect on the listing of the Company's shares on Nasdaq.
Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "We will submit a definitive plan to Nasdaq on a timely basis and proceed to regain compliance."
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on accesswire.com
FAQ
What recent action did Nasdaq take against Cosmos Health?
What forms did Cosmos Health fail to file?
What are the potential consequences for Cosmos Health's stock (COSM)?
What is the deadline for Cosmos Health to submit a compliance plan?
Can Cosmos Health get an extension to meet compliance requirements?
What did the CEO of Cosmos Health say about the delinquency letters?
